StockData

Aspire-Lakewood vs Vyome

ASBP and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASBP and HIND compare

Aspire-Lakewood and Vyome are about the same size, with market caps of $11.3M and $10.7M.

Vyome keeps more of each dollar of sales as profit, with a net margin of −8717% compared with −11314% at Aspire-Lakewood.

Aspire-Lakewood scores higher on the StockData Score (2 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASBPHIND
Size and price
Market cap$11.3M$10.7M
Share price$8.06$1.53
Change, 1 year91.5%−69.0%
Change, 5 years–−100.0%
Beta (5Y)–1.61
Employees–18
StockData Score
Total score2 (better)1
Valuation score1 (better)0
Growth score00
Performance score00
Health score11
Dividend score00
Valuation
P/S116×82.8× (better)
P/B1.0×–
Growth
Revenue growth (TTM)–−67.1%
Revenue growth, 5Y average–−51.0%
Profitability
Gross margin−25.0%52.7% (better)
Operating margin−7495% (better)−9190%
Net margin−11314%−8717% (better)
Return on equity−1032%−194% (better)
Return on invested capital–−173%
Financial health
Interest coverage−0.8× (better)−285.8×
Current ratio7.99 (better)4.37
Altman Z-score−0.21 (better)−13.61
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield–40.0%
Shareholder yield0.00%40.0% (better)
Ownership
Held by institutions–2.0%
Held by insiders1.4%6.8%
Short interest, % of float–0.28%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.